Sanofi will not be pursuing approval of tolebrutinib for PPMS, and an FDA decision on the therapy in nonrelapsing SPMS will ...

The FDA has delayed tolebrutinib’s review date again, as Sanofi also posted a Phase III failure for the MS candidate.

Shares of Sanofi SNY fell nearly 2% on Monday after the company reported two setbacks in connection with its investigational ...

Tolebrutinib failed to meet the primary endpoint in the phase 3 PERSEUS study involving patients with primary progressive multiple sclerosis.

Discusses Year-End Late-Stage Pipeline Review With Focus on Clinical and Regulatory Developments December 16, 2025 11:15 AM ...

Sanofi has agreed $1.7bn and $1.04bn licensing deals with Dren Bio and ADEL, respectively. Following the disappointment of a ...

The PERSEUS trial was a global, double-blind, randomized Phase 3 study comparing tolebrutinib to placebo in PPMS patients.

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Kyverna Therapeutics announced positive topline data from a phase II trial of mivocabtagene autoleucel, a chimeric antigen ...

The ECB meets on Thursday and is widely expected to hold its key rate at 2% for a fourth straight meeting. Traders will be ...

Eli Lilly’s retatrutide exceeds expectations in Phase III, capping off a sparkling 2025 for the obesity titan; an internal ...